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V. Warty, S. Mehta. S. Todo, and T.E. Starzl 
CYCLOSPORINE (CyA) has been used in onhotopic liver transplantation ~liqxF for over 10 years. while 
FK 506 has been in use for the last 2 years! at the 
University of Pittsburgh. It has been shown that CyA 
dosage in pediatric OLTx is higher compared to adult 
OLTx. possibly owing to rapid metabolism in children 
and/or poor absorption from Roux-en-Y loop often used 
for biliary reconstruction.; It is also known that absorption 
ofCyA is dependent on the presence of bile in the gut. J We 
have shown FK 506 abso."tlon does not change with the 
presence or absence of bile both in humansu :md in 
animals. b We have also observed that the half·life of FK 
506 in children IS about two times smaller. the clearance IS 
nearly two to four times more rapid. and the volume of 
distribution IS 1.8 times higher as compared to adults with 
comparable liver function In the immediate posttransplant 
period (unpublished datal. The present study compares 
how the above differences reftect in actual clinical practice 
following OL Tx in adults and children. both in terms of 
intravenous tIV) and omi (PO) therapy. In addition. we 
a1so compared the trough levels of FK 506 (in plasma) and 
CyA (whole blood TDx) in adults and children. 
MATERIAL AND METHODS 
We selected the first 20 consecutive adult primary OLTx ~trans­
planted between August to October 19891 and the first 20 pediatnc 
(aile <II vears' OLTx (transplanted between November 1989 to 
Julv 1990) who were treated with FK 506 and were alive without 
retransplantallon at the end of I year. We selected 20 adult and 20 
pedlatnc OLTx (matched for theIr age and weIght) treated WIth 
CyA for companson. Mean age of the adults for the FK S06group 
was 41.1 (SD 9.9) years and mean body weIght was 74.3ISD IS.4) 
kg. Mean age and weight for the CyA group was 42.3 years ~pl 
13.4) and 71.1 (SO 8.1l kg. respectively. Mean age of the pediatric 
FK S060LTx was 2.1 (SO 1.4) years and weight was 10.7 (S04.2) 
kg and the mean age and weIght for the CyA group was 2.1 (SO 
1.6) years and 11.3 (SO 4.0) kg. respectively. CyA was com· 
menced as IV 5 mgtkgld in two divided doses 10 adult OLTx and 
6 mgtkgld in three dIVIded doses In pediatnc OL Tx. FK S06 was 
given as O.IS mgtkgld in tWO divided shon infusions over 2 to 4 
hours to both adults and clilldren (CllJ'mlt dose of FK S06 is 0.1 
mglkgld as a continuous infusion I. Subsequent adjustments In the 
dosage were made based on trough concentrations. he!)atlc func-
tion. renal function. side effects from the drug. history of rejection 
episodes. and presence of infection in all patient groups. Oral 
therapy was commenc:ed once patients c:ould tolerate oral ftuids. 
Intravenous therapy was discontinued if sufficient level of the 
drug could be mamtained in plasma/whole blood. Daily dose of 
FK S06 and cyclosponne were recorded for a penod of 12 months 
In each patient: weIght-adjusted doses were calculated for weeks 
I. ~K 3. 4. 5-6. 7-8. 9-12. IJ-16. 17-20.21-24.25-32.33-40. and 
.j I-52 posttransplant based on corresponding mean bodv weIghts. 
~edian value of trough plasma levels of FK 506 and trough 
whole-blood CyA level for each patient was obtained for the 
above time interval. Further. median value for the level was 
obtained in each group of patients for companson. 
Statistical Analysis 
Comparisons across lime and comparisons between children and 
adult dose requirements were done by repeated measures analysis 
of variance. Friedman's test was used to test changes In median 
trough plasma levels of FK S06 and trough whole-blood CyA 
levels over time. Comparison between children and adults median 
plasma levels of FK S06 and whole-blood levels for Cy A were 
carried out uSing Wilcoxon rank sum test. The mean number of 
days of IV Cy A and IV FK S06 for both chIldren and adults were 
compared using the standard two sample Student's t test. Due to 
multiple tesllng. the level of significance was adjusted uSing 
Bonferront's correction. 
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Tibia 1. IV CVAlFK 508 Adulta Ind Child,." 
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Inl_ Mullllll ChiIcIrm {CI RatiO {CI., AduIII{" C~{CD RatiO (Clal 
Weetl. 1 4.7 (10) 7.5 (2.6) 157 0.13 (0.02) 0.11 (0.03) 0.88 
Weetl.2 2.4 (2.1 ) 6.8 (43) 2.8 0.015 (0.03) 0.035 (0.05) 2.33 
W&eI<3 75 (.95) 3.9 (3.8) 5.0 0.008 (.008) 009 (0.031 1.13 
Weetl. 4 376 (.913) 2.26(2.8) 6.0 0.009 (0.021 
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Fig 1. Demonstrates prolonged use IV treatment In CyA group oj 
pabents with need to combine IV and oral treaunent. whereas In 
FK 506 group oj pabents there IS no need tor combined IV and oral 
treatment. 
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Fig 2. Mean::!: SO oral dose 01 CyA In adultS (0) and children 
(0) over weekS 5 to 52 posttransPlMt. 
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Fig 3. (A) Direct companson of mean oral dose of eyA in adults 
(solid bar, and children (hatched bar) from weekS 1 to 52 post-
transplant. (B) Compares mean FK 506 oral dose In adults and 
pediatnc OL Tx for the same paned. 
RESULTS 
Intravenous Treatment 
As shown in Table 1. children required 1.6 to 6.0 times 
higher Cy A in the first 4 weeks compared with adults while 
FK 0506 requirement was 0.9 to 2.33 times higher in 
children. The overall mean dose ofCyA in adults was 2.07 
(SO 1.32) mgtkg/d for the first 4 weeks and that for children 
was 05.1 (SD 3.45) mgtkg/d. This difference IS statistically 
significant I P < .00 I), Mean i V FK 0506 dose for adults was 
0.005 (SD 0.03) mgtkg/d and that for children was 0.04 (SO 
0.03) mgtkg/d for the Similar penod: the difference IS not 
significant IP =6(8). 
Mean total number of days oi IV CyA therapy in 
children was 205.4 (SO 11.3) days while that In adults was 
\5.2 (SO 5.9) days. The difference IS Significant IP < .(01). 
The mean days of IV FK 506 therapy in children was 9.0 
(SO 05.3) days and that in adults was 7.5 (SO 2.3) days (p = 
K~PUFK 
There was a penod of overlap with ora! and IV CyA 
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evA AND FK 506 REQUIREMENTS IN OLTx 
therapy with a mean of9.3 days in adults and mean of 18.3 
days in children. This period of overlap was < I day in 
pediatric and adult patients receiving FK 506. as shown In 
Fig 1. 
Oral Treatment 
The mean dose requirement of oral Cy A in all adults varied 
from 0.2 mg/kg/d to 16.S mg/kg/d for week S to week S2 
post-OLTx (mean 9.4. SO 4.S). respectively. The mean 
Cy A requirements for children varied from 24.8 mg/kg/d to 
56.4 mgtkg/d (mean 46.1. SO 30.8) over the same intervals 
(Fig 2). As shown in Fig 3A. children requIred 3.4 to 5.0 
times (overall mean ratio 4.9. SE 0.9) the oral dose ofCyA 
than that of adults. 
The mean requirement of FK 506 in adults varied from 
O.IS mgtkg/d to 0.22 mg/kg/d for weeks 4 to 52 posttrans-
plantation (mean 0.17. SO 0.09). The FK 506 reqUIrements 
for children vaned from 0.24 mgtkg/d to 0.37 mgtkgtd 
I mean 0.33. SO 0.17) for the same mterval (fig 41. Children 
i'cqulred 1.60 to 2.14 times the oral dose of FK 506 than 
that oi adults (overall mean ratio 1.95. SE 0031) (Fig 3B). 
Ninetv-rive percent confidence intervals were generated 
for the overall mean ratio of CyA and fK 506 reqUIre-
ments. These intervals did not overlap. indicating that the 
oral requIrements of Cy A in children are Significantly 
higher IP < O.OS) than those of FK 506. 
Measurements of Drug Level 
All patients were monitored with frequent trough level 
measurement of drug in plasma (FK 5(6) or whole blood 
(Cy A). A total of approximately 4.000 observallons in drug 
levels were made in the follow-up period of I year for all 
four groups of patients. These levels were grouped to-
1.00 r 
0.'0 t 
0.80 
:;: 
• 0.70 
'0 
C. 
... 0.60 C. 
E 
CD 0.50 
a 
Lt'l 0.40 :><: 
I I 
14. I C;; 0.30 t-O 
0.20 
0.10 
a 
I I a 1 K~ l 
0.00 ' 
WEEKS 
a Adults o Childr,n 
FIg 4. Mean oral dose of FK 506 In adults (0) and pedl8tnc OL Tx 
(0) WIth SO over Weef(S 5 to 52 posUI'anSOIant. 
'. 
,. 
'. 2 
" 
z 0 
-
• 
-
2765 
MEDIAN CYA WHOLE BLOOD TROUGH LEVEL 
0 
0 g 
0 g • 
• • 0 
• 
'! • .. 
.:. 
-
.. 
.; 
WI!I!KS 
o 
• 
. 
.;, 
o 
• 
0 
N 
.:. 
• MlULn 
o~ 
g • • 
00' 
o 
. .. 0 N 
N ~ ~ .. 
.. .. 
N N .. . 
Fig 5. Median eyA whole-blood trough levelS for adUlts and 
pedlatnc OL Tx from weeKs 1 to 52 posttransplant. 
gether for the similar time period for each pattent as 
uescnbed earlier. The median value for each patient for the 
given interval was obtained. Median value from 20 patients 
m each group showed no difference despite the fact that 
children received much higher dosages of the drug (Figs 5 
and 6). 
DISCUSSION AND CONCLUSIONS 
Because of rapid metabolism of the drugs tn children. the 
Jose requirements (mg/kg/d) for CyA and FK 506 are 
higher than in adults. Prolonged IV therapy of Cy A both in 
(hildren and in adults often is required because of poor 
absorption of the orally administered Cy A during the 
Immediate posttransplant period and the dependence of 
this absorption upon bile salts. Children also reqUire more 
FK S06 than adults. but the drug IS less dependent on bile 
for good oral absorption. Panly for this reason. double-
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Fig 8. Median FK 506 plasma trough levels for adultS and 
children OL Tx from weelca 1 to 52 posnranspl8nt. 
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route administration for prolonged periods is not required 
when oral FK 506 administration is resumed. 
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